Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 19, 2019
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
|
| | | | |
Florida | | 001-35887 | | 26-279552 |
(State or other jurisdiction | | (Commission | | (IRS Employer |
of incorporation) | | file number) | | Identification No.) |
1775 West Oak Commons Ct., NE, Marietta GA 30062
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (770) 651-9100
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
None | | n/a | | n/a |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
| |
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Resignation of Luis A. Aguilar as a Director
(b) Luis A. Aguilar resigned from the Board of Directors of MiMedx Group, Inc. (the “Company”) on September 19, 2019. Mr. Aguilar's resignation was not as a result of a disagreement with the Company.
|
| |
Item 7.01 | Regulation FD Disclosure. |
On September 20, 2019, the Company issued a press release announcing the resignation of Luis A. Aguilar from the Company's Board of Directors. A copy of the press release is furnished as Exhibit 99.1 to this report.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | MIMEDX GROUP, INC. |
| | |
Date: September 20, 2019 | By: | /s/ Timothy R. Wright |
| | Chief Executive Officer |
Exhibit
Exhibit 99.1
MiMedx Announces Resignation of Board Member
Mr. Luis A. Aguilar Resigned Effective September 19, 2019
MARIETTA, Ga., September 20, 2019 -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors. The Board expresses its appreciation for his service.
Dr. Kathleen Behrens Wilsey, Chair of the MiMedx Board of Directors, stated, “On behalf of the Board and the Company, we thank Luis for his commitment and contributions. We appreciate the leadership he provided as we made a vital transition and returned our full attention to healthcare professionals dedicated to addressing patient needs. We wish him our very best and look forward to his continued support.”
Mr. Aguilar noted, “After a difficult period, I believe the Company is well situated to refocus itself on industry leadership through product and pipeline innovation. It is gratifying to have been part of this effort to reorient the Company toward the future. I am confident that the Company is well positioned to serve the interests of its shareholders, patients and employees.”
About MiMedx
MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date. For additional information, please visit www.mimedx.com.
Contact: